Oxford Gene Technology (OGT), Oxford, UK, a molecular genetics company, has expanded the content of its SureSeq myPanel next-generation sequencing (NGS) custom cancer panel, which now covers 120 fully optimized cancer-related genes. The expanded content gives researchers greater freedom to customize their sequencing experiments, enabling focus on regions of interest and saving both time and cost.
OGT’s expert-curated, solid tumor and hematology custom panel enables users to sequence only the genes and regions relevant to their cancer research, which increases throughput and saves on sequencing reagents. The rigorously preoptimized panel content facilitates the development of robust NGS assays, even when working with challenging sample types, such as formalin-fixed paraffin-embedded (FFPE) tissue, or on genes that are difficult to sequence, either because of their high GC content or because they are in areas of the genome that are repetitive by nature, such as internal tandem duplications.
OGT’s unique panel design and advanced hybridization-based target enrichment delivers unparalleled coverage uniformity. This enables consistent and confident detection of low-frequency variants while simultaneously minimizing the need for supplementary fill-in with Sanger sequencing.
Researchers can select content from a wide range of NGS panel content available for solid tumors covering breast cancer, colorectal cancer, glioma, lung cancer, melanoma, ovarian cancer, prostate cancer, and sarcoma. For hematology malignancies, the panel content covers acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, myelodysplastic syndromes, myeloid malignancies, and myeloproliferative neoplasms.
In addition to the expanded content, OGT completed successful beta trials of the latest version of the SureSeq Interpret software, an NGS data analysis pipeline provided free with SureSeq panels. This software, which is the NGS counterpart of OGT’s CytoSure Interpret microarray software, supports NGS panel users with an easy-to-use and improved, modular pipeline, database, and user interface with multiple deployment options; dynamic filtering; and a customizable reporting structure for simple NGS data processing and interpretation.
“Our ever-increasing custom panel content along with NGS-specific software development highlights our commitment to providing customers with the best-performing and most convenient NGS products on the market,” says David Cook, senior product manager at OGT. “It also shows how responsive we are as a company and that we have listened to the needs of our customers with respect to the additional capabilities of our data analysis pipeline to accompany our panels, which we expect to deliver very soon.”
To learn more, visit Oxford Gene Technology.